{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:15Z","timestamp":1772119515927,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The majority of melanoma patients experience relapse during adjuvant therapy or after the end of therapy. Sixty-one patients from 3 melanoma centres who experienced recurrence and received adjuvant pembrolizumab for resected stage III\/IV melanoma were enrolled. Disease characteristics, recurrence characteristics, subsequent management and outcomes were retrospectively analysed. Sixty-one patients were enrolled in this study. The median time to first relapse from the commencement of adjuvant pembrolizumab was 8 months (1\u201322 months). The first recurrences were locoregional alone in 25 patients (41%), distant alone in 29 (47.5%) and concurrent locoregional and distant relapse in 7 (11.5%). At the first recurrence, 4 patients (80%) who underwent resection alone experienced further relapse of disease. Three (60%) patients who were treated with adjuvant pembrolizumab following surgery, 2 (100%) patients who were treated with adjuvant chemotherapy, 2 (66.7%) patients who were treated with adjuvant chemotherapy and pembrolizumab combined and 3 (100%) patients who were treated with adjuvant radiotherapy and pembrolizumab combined had further recurrence. Of the three patients treated with adjuvant BRAF\/MEKi following the first relapse, none had yet recurred. Of the 8 patients treated with pembrolizumab alone, only one patient (12.5%) who recurred after ceasing adjuvant PD1 had a partial response. The overall response rate to BRAF\/MEKi was 75%, 3\/4; to pembrolizumab in combination with an oral multitargeted receptor tyrosine kinase inhibitor, it was 22.2%, 2\/9; to chemotherapeutic agents alone, it was 33.3%, 1\/3; and to chemotherapeutic agents combined with pembrolizumab, it was 37.5%, 3\/8. The patient treated with imatinib had progressive disease after 3 months of treatment. Of the 6 patients who received temozolomide combined with pembrolizumab, 3 (3\/6, 50%) had a partial response. The median OS of the patients who relapsed locoregionally only was longer than that of the patients who relapsed distally at the first recurrence (35 months and 14 months, respectively; P &lt; 0.01). The outcomes of the patients with disease recurrence during or after the completion of 1 year of adjuvant anti-PD1 therapy were poor despite multimodality treatment.<\/jats:p>","DOI":"10.1007\/s10637-023-01348-5","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T05:03:03Z","timestamp":1682312583000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study"],"prefix":"10.1007","volume":"41","author":[{"given":"Dong-Dong","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3978\/j.issn.2305-5839.2015.12.23","volume":"3","author":"J Guo","year":"2015","unstructured":"Guo J et al (2015) Chinese guidelines on the diagnosis and treatment of melanoma (2015 Edition). Ann Transl Med 3:322. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.12.23","journal-title":"Ann Transl Med"},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"key":"1348_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109\u20131117. https:\/\/doi.org\/10.1016\/S0140-6736(14)60958-2","journal-title":"Lancet"},{"key":"1348_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s10637-020-00913-6","volume":"38","author":"T Li","year":"2020","unstructured":"Li T, Jia DD, Teng LS (2020) Adjuvant pembrolizumab versus high-dose interferon alpha-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. Invest New Drugs 38:1334\u20131341. https:\/\/doi.org\/10.1007\/s10637-020-00913-6","journal-title":"Invest New Drugs"},{"key":"1348_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1470-2045(21)00125-X","volume":"22","author":"A Indini","year":"2021","unstructured":"Indini A, Grossi F (2021) Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG\/KEYNOTE-054 trial. Lancet Oncol 22:573\u2013575. https:\/\/doi.org\/10.1016\/S1470-2045(21)00125-X","journal-title":"Lancet Oncol"},{"key":"1348_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen CN et al (2020) Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(). Ann Oncol 31:1075\u20131082. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.471","journal-title":"Ann Oncol"},{"key":"1348_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.48095\/ccko202173","volume":"34","author":"M Ziaran","year":"2021","unstructured":"Ziaran M, Dvorak P, Hoffmann P, Kopecky J (2021) Failure of adjuvant treatment for malignant melanoma - what next? Klin Onkol 34:73\u201377. https:\/\/doi.org\/10.48095\/ccko202173","journal-title":"Klin Onkol"},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ et al (2021) Pembrolizumab plus ipilimumab following Anti-PD-1\/L1 failure in melanoma. J Clin Oncol 39:2647\u20132655. https:\/\/doi.org\/10.1200\/JCO.21.00079","journal-title":"J Clin Oncol"},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","volume":"29","author":"J Guo","year":"2011","unstructured":"Guo J et al (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904\u20132909. https:\/\/doi.org\/10.1200\/JCO.2010.33.9275","journal-title":"J Clin Oncol"},{"key":"1348_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641\u2013648. https:\/\/doi.org\/10.1007\/s00262-006-0225-8","journal-title":"Cancer Immunol Immunother"},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-14-0301","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, Larmonier N (2014) Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res 74:2663\u20132668. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0301","journal-title":"Cancer Res"},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","journal-title":"Cancer Cell"},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","volume":"9","author":"Y Yan","year":"2018","unstructured":"Yan Y et al (2018) Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol 9:1739. https:\/\/doi.org\/10.3389\/fimmu.2018.01739","journal-title":"Front Immunol"},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"Vera Aguilera J et al (2020) Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res 30:364\u2013375. https:\/\/doi.org\/10.1097\/CMR.0000000000000669","journal-title":"Melanoma Res"},{"key":"1348_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.21037\/atm-21-5738","volume":"9","author":"T Hu","year":"2021","unstructured":"Hu T et al (2021) Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China. Ann Transl Med 9:1625. https:\/\/doi.org\/10.21037\/atm-21-5738","journal-title":"Ann Transl Med"},{"key":"1348_CR17","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild A et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823\u20132830. https:\/\/doi.org\/10.1200\/JCO.2007.15.7636","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01348-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01348-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T17:35:54Z","timestamp":1687541754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01348-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01348-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2242441\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"6 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dong-Dong Jia declares that he has no conflict of interest. Yu Xu declares that he has no conflict of interest. Ting Li declares that he has no conflict of interest. Ji-Long Yang declares that he has no conflict of interest. Yong Chen declares that he has no conflict of interest. Tao Li declares that he has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}